Quinn Opportunity Partners LLC Grows Position in uniQure (NASDAQ:QURE)

Quinn Opportunity Partners LLC raised its position in shares of uniQure (NASDAQ:QURE) by 187.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 69,000 shares of the biotechnology company’s stock after buying an additional 45,000 shares during the quarter. Quinn Opportunity Partners LLC’s holdings in uniQure were worth $1,219,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of QURE. Raymond James Financial Inc. acquired a new stake in shares of uniQure in the fourth quarter valued at about $1,951,000. Invesco Ltd. increased its holdings in uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company’s stock valued at $10,836,000 after buying an additional 502,684 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of uniQure during the 4th quarter valued at approximately $177,000. Wells Fargo & Company MN raised its holdings in shares of uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 1,503 shares during the period. Finally, Rangeley Capital LLC acquired a new stake in uniQure during the fourth quarter worth about $295,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Price Performance

Shares of QURE opened at $8.93 on Friday. The firm’s 50 day moving average price is $12.28 and its 200 day moving average price is $11.07. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The firm has a market cap of $482.91 million, a PE ratio of -1.80 and a beta of 0.42. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 28,341 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the transaction, the chief executive officer now owns 651,454 shares in the company, valued at approximately $6,703,461.66. The trade was a 4.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 90,830 shares of company stock worth $961,401. Corporate insiders own 4.74% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on QURE shares. Mizuho raised their target price on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. Wells Fargo & Company lowered their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. StockNews.com raised uniQure to a “sell” rating in a report on Tuesday, March 11th. Finally, Chardan Capital started coverage on shares of uniQure in a research report on Tuesday, April 1st. They issued a “buy” rating and a $38.00 price target for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and a consensus price target of $38.80.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.